Covered recipient · General Payments record
HARVEY J SANDERS
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,591.37
- Reported across 170 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $282.69 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $68.80 | 4 |
| Novo Nordisk AS | $59.60 | 3 |
| ABBVIE INC. | $50.51 | 3 |
| Abbott Laboratories | $41.96 | 3 |
| Lilly USA, LLC | $31.57 | 2 |
| Acerta Pharma LLC | $16.95 | 1 |
| Astellas Pharma US Inc | $13.30 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $14.15 | 03/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124906214 | CMS |
| Abbott Laboratories | $14.09 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124906216 | CMS |
| Abbott Laboratories | $13.72 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124906218 | CMS |
| ABBVIE INC. | $20.47 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106013635 | CMS |
| ABBVIE INC. | $14.01 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106013637 | CMS |
| ABBVIE INC. | $16.03 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106013639 | CMS |
| Astellas Pharma US Inc | $13.30 | 07/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139372129 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.95 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104281167 | CMS |
| Lilly USA, LLC | $18.50 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134979872 | CMS |
| Lilly USA, LLC | $13.07 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134979874 | CMS |
| Novo Nordisk Inc | $17.70 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097350874 | CMS |
| Novo Nordisk Inc | $24.81 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097209047 | CMS |
| Novo Nordisk Inc | $17.09 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097270867 | CMS |
| PFIZER INC. | $19.16 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130952489 | CMS |
| PFIZER INC. | $18.90 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131166161 | CMS |
| PFIZER INC. | $15.37 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131230463 | CMS |
| PFIZER INC. | $15.37 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131231259 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.